AU2002323894B2 - Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use - Google Patents
Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use Download PDFInfo
- Publication number
- AU2002323894B2 AU2002323894B2 AU2002323894A AU2002323894A AU2002323894B2 AU 2002323894 B2 AU2002323894 B2 AU 2002323894B2 AU 2002323894 A AU2002323894 A AU 2002323894A AU 2002323894 A AU2002323894 A AU 2002323894A AU 2002323894 B2 AU2002323894 B2 AU 2002323894B2
- Authority
- AU
- Australia
- Prior art keywords
- lymphocytes
- human
- monoclonal antibody
- polypeptide
- costimulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 197
- 229920001184 polypeptide Polymers 0.000 title claims description 175
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 175
- 238000002360 preparation method Methods 0.000 title description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 302
- 230000004940 costimulation Effects 0.000 claims description 110
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 67
- 230000014509 gene expression Effects 0.000 claims description 57
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 52
- 210000004027 cell Anatomy 0.000 claims description 47
- 210000004408 hybridoma Anatomy 0.000 claims description 46
- 230000000284 resting effect Effects 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 41
- 239000012634 fragment Substances 0.000 claims description 39
- 230000000139 costimulatory effect Effects 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 36
- 102000036639 antigens Human genes 0.000 claims description 36
- 108091007433 antigens Proteins 0.000 claims description 36
- 230000035755 proliferation Effects 0.000 claims description 35
- 230000004071 biological effect Effects 0.000 claims description 32
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 claims description 30
- 238000000684 flow cytometry Methods 0.000 claims description 27
- 238000010790 dilution Methods 0.000 claims description 26
- 239000012895 dilution Substances 0.000 claims description 26
- 210000000822 natural killer cell Anatomy 0.000 claims description 25
- 210000004443 dendritic cell Anatomy 0.000 claims description 24
- 210000003714 granulocyte Anatomy 0.000 claims description 24
- 210000001616 monocyte Anatomy 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 16
- 230000006698 induction Effects 0.000 claims description 16
- 210000000987 immune system Anatomy 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims description 13
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims description 13
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 11
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 11
- 102100035304 Lymphotactin Human genes 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 230000006907 apoptotic process Effects 0.000 claims description 9
- 230000001684 chronic effect Effects 0.000 claims description 9
- 238000001502 gel electrophoresis Methods 0.000 claims description 9
- 229920002401 polyacrylamide Polymers 0.000 claims description 9
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 8
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 8
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 210000005259 peripheral blood Anatomy 0.000 claims description 7
- 239000011886 peripheral blood Substances 0.000 claims description 7
- 208000030507 AIDS Diseases 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000010186 staining Methods 0.000 claims description 6
- 241000699670 Mus sp. Species 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000001744 histochemical effect Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000002555 ionophore Substances 0.000 claims description 3
- 230000000236 ionophoric effect Effects 0.000 claims description 3
- 238000004848 nephelometry Methods 0.000 claims description 3
- 210000004989 spleen cell Anatomy 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims 63
- 230000005764 inhibitory process Effects 0.000 claims 48
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 238000004519 manufacturing process Methods 0.000 claims 7
- 230000016784 immunoglobulin production Effects 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 6
- 208000026278 immune system disease Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000003248 secreting effect Effects 0.000 claims 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims 1
- 235000009685 Crataegus X maligna Nutrition 0.000 claims 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims 1
- 235000009486 Crataegus bullatus Nutrition 0.000 claims 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims 1
- 235000009682 Crataegus limnophila Nutrition 0.000 claims 1
- 235000004423 Crataegus monogyna Nutrition 0.000 claims 1
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 235000002313 Crataegus paludosa Nutrition 0.000 claims 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims 1
- 101100182721 Mus musculus Ly6e gene Proteins 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 31
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 31
- 230000004913 activation Effects 0.000 description 25
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 18
- 239000002299 complementary DNA Substances 0.000 description 15
- 210000002741 palatine tonsil Anatomy 0.000 description 14
- 239000000126 substance Substances 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 101100013500 Solanum lycopersicum 2A11 gene Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 3
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 108020005096 28S Ribosomal RNA Proteins 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101150100936 CD28 gene Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000995194 Homo sapiens Nebulette Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- 102100034431 Nebulette Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 108010019677 lymphotactin Proteins 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
P/00/011 28/5/91 Regulation 3.2(2)
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Application Number: Lodged: Invention Title: COSTIMULATING T-CELL POLYPEPTIDE, MONOCLONAL ANTIBODIES, THEIR PREPARATION AND USE The following statement is a full description of this invention, including the best method of performing it known to us S It *I 1 Costimulating polypeptide of T cells, monoclonal antibodies, and the preparation and use thereof The invention relates to a polypeptide (8F4 molecule) having the biological activity of costimulating T cells. The invention further relates to monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal antibodies. The invention additionally relates to the use of substances which inhibit the biological activity of the polypeptide 8F4 according to the invention, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, as pharmaceuticals.
In particular, the invention relates to the use of these substances for the prevention or therapy of disorders in which the immune system is involved, in particular for the treatment of autoimmune diseases and for the prevention of rejection reactions with organ transplants. The invention additionally relates to the use of the 8F4 molecule or of cells which contain the 8F4 molecule as pharmaceuticals, in particular for the prevention or therapy of disorders in which the immune system is involved, in particular for the treatment of cancers, Aids, asthmatic disorders or chronic viral diseases such as HCV or HBV infections. The invention further relates to the use of substances which specifically recognize the polypeptide according to the invention, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for the diagnosis of disorders in which the immune system is involved. In particular, the invention relates to diagnosis by means of an ELISA detection, a flow cytometry or a Western blot, a radioimmunological detection, a nephelometry or a histochemical staining.
T lymphocytes recognize their antigen, which is presented by "antigen-presenting cells", for example dendritic cells, B cells and macrophages, through their ~Cs l 2 T-cell receptor. Recognition of the antigen by the T-cell receptor alone is, however, in most cases insufficient for adequate activation of T lymphocytes.
The latter makes additional simultaneous stimulation (also called "costimulation" hereinafter) by other receptor molecules on the surface of the T lymphocytes necessary. One of these receptor molecules is the socalled CD28 receptor which is stimulated by the costimulating molecule B7. If these "costimulatory" molecules, for example CD28, are effective, then the activation of the T cell reaches an adequate level after recognition of the antigen by the T-cell receptor. After such a complete activation, the T cell expresses additional molecules, for example CD25, CD69, CD71, on the surface and synthesizes numerous cytokines, for example IL-2 and IFN-y, which function as messengers. Both these additional surface molecules and the cytokines serve for the T cell to exchange information with other cells in the immune system. The activated T cells direct the entire antigen-specific immune defences through the additional surface molecules and the cytokines. Both the generation of cytotoxic cells ("killer cells") and the generation of antigen-specific antibodies by B cells is controlled in this way. Cytotoxic cells, as well as the specifically formed antibodies, eliminate viral or bacterial pathogens which enter the body. In some cases, however, the immune response goes too far, and the immune system is directed against the body's own cells. This leads to the occurrence of "autoimmune diseases", for example to rheumatoid arthritis, ankylosing spondylitis, Sj6gren's syndrome, ulcerative colitis inter alia. One of the essential sites of cooperation between antigenactivated T cells and other cells of the immune system are the secondary lymphatic organs, including the tonsils. This is where the T lymphocytes are activated by the antigen presented by dendritic cells, and this 3 is where T lymphocytes interact with B cells. Through this interaction, B cells secrete, after several intermediate stages of differentiation, antigenspecific antibodies of the IgM and IgG types.
The costimulatory molecule which has been characterized best and is among the most effective to date is the CD28 surface molecule (called CD28 receptor or CD28 hereinafter) which is constitutively expressed on a large fraction of T cells. Costimulation by CD28 in vitro leads, after recognition of the antigen by the T-cell receptor, to a very large increase in cytokine secretion, for example of IL-2 and IFN-y, and to a marked up-regulation of the expression of cell surface molecules such as CD25, CD69, CD71, which are necessary for interaction of T cells with other immune cells, for example B lymphocytes; cf. Chambers and Allison, Current Opinion in Immunology 9 (1997), 396-404.
Costimulation via the CD28 receptor can also markedly increase the proliferation of T lymphocytes. In addition, costimulation 'via the CD28 receptor optimizes the T-cell control of B-lymphocyte function so that there is increased secretion of antibodies.
If the function of the CD28 receptor is abolished, there is a drastic loss of function in the immune defences. This has been shown by means of a transgenic mouse in which the CD28 gene was destroyed by homologous recombination (a so-called "CD28 knockout"). The destruction in this way of activation of the antigen-specific T cells leads to lack of costimulation. This in turn leads to a disturbance of T-cell function, that is to say to a reduced proliferation of T cells and to a drastically reduced synthesis of various cytokines. The lack of costimulation eventually leads to a reduced function of the antigen-specific immune defences. Thus, inter alia, the formation of antigen-specific IgGl and IgG2 antibodies by B lymphocytes is reduced to 10% of the 1 11 (0 4 normal level through the lack of CD28; cf. Shahinian et al., Science 262 (1993), 609-612; Lucas et al. Journal of Immunology 154 (1995), 5757-5768. It is also possible in vitro to prevent the Aids virus entering T lymphocytes by costimulation by CD28; cf. Riley et al., Journal of Immunology 158 (1997), 5545-5553.
Corresponding experiments in vivo have not yet been carried out. It is known that CD28 switches on many cytokine genes which may lead to considerable side effects in vivo. Blockade of CD28 receptors by a soluble CTLA-4 immunoglobulin molecule has been employed successfully in a monkey model to prevent the rejection of transplanted kidneys. In this case, CTLA-4 had been employed in combination with an antibody against the CD40 ligand molecule; cf. Kirk et al., Proc. Natl. Acad. Sci. USA 94 (1997) 8789-8794.
However, blockade of CD28 receptors affects all T lymphocytes and not just those already activated because CD28 is constitutively expressed on T lymphocytes.
There is thus a need for a costimulating surface molecule which is expressed only on activated T lymphocytes. The invention is therefore based on the object of providing a surface molecule on activated T cells which has a strong costimulatory effect on central functions of T lymphocytes. Another object of the invention is to provide substances, for example monoclonal antibodies against the costimulatory surface molecule, natural or synthetic ligands, agonists or antagonists of the surface molecule.
In a first embodiment, the invention relates to a polypeptide having the biological activity of costimulation of T cells, characterized in that a) the polypeptide occurs on activated CD4' and CD8 T lymphocytes but not on resting or activated B cells, granulocytes, monocytes, NK cells (natural killer cells) or dendritic cells, and b) the polypeptide is a 4 ri 5 dimer, the polypeptide having a molecular weight of about 55 to 60 kDa (kilodalton) determined in a nonreducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), and the two polypeptide chains of the polypeptide having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing
SDS-PAGE.
The polypeptide according to the invention (also called 8F4 molecule or 8F4 hereinafter) is expressed only after activation of the T lymphocytes, specifically both on CD4* and on CD8* T cells. In a nonreducing SDS-PAGE, the 8F4 molecule has a molecular weight between about 55 and 60 kDa (kilodalton). The 8F4 molecule is composed of two peptide chains, and the two peptide chains have a molecular weight of about 27 and about 29 kDa in a reducing SDS-PAGE. The 8F4 antigen can be unambiguously detected histologically on activated T lymphocytes in the lymphatic tissue of the tonsils and lymph nodes, especially in the germinal centres, the site of interaction of T lymphocytes and B lymphocytes in the generation of antibodies. Tonsillar T cells isolated ex vivo are about 50-80% positive for the 8F4 antigen and show signs of advanced activation.
The 8F4 molecule is not detectable on resting or activated B cells, granulocytes, monocytes, NK cells and dendritic cells.
An important biological activity of the 8F4 molecule is its costimulating activity on T lymphocytes. The costimulating activity can be determined by the method of Linsley et al., Journal of Experimental Medicine 176 (1992), 1595-604. The costimulating activity of the 8F4 molecule resembles the costimulating activity of the CD28 molecule, which has been identified as the central enhancement element of antigen recognition by the immune system. The 8F4 molecule differs in many aspects from CD28, however.
Thus, expression of the 8F4 molecule on the surface of
^C
o_ 6 the T cells requires induction, whereas CD28 is constitutively expressed. There are also distinct differences detectable in the function: costimulation by CD28 leads to overexpression of numerous lymphokines, inter alia of interleukin-2 (IL-2).
Costimulation by 8F4 also leads to enhanced secretion of lymphokines, but not of IL-2. The costimulatory activity of the 8F4 molecule thus differs from the activity of the CD28 molecule. Since stimulation by 8F4 does not switch on all cytokine genes, costimulation by 8F4 in vivo is advantageous, for example compared with costimulation via the CD28 receptor. Moreover, the induction, the expression, the site of expression and the function of the 8F4 molecule differ from all other known molecules with costimulatory activity.
The 8F4 molecule according to the invention is a novel surface molecule on activated T cells which has a strong costimulatory effect on central functions of T lymphocytes. Expression in vivo indicates inter alia an essential involvement of the 8F4 molecule in the cooperation of T cells with other cells of the immune system such as B cells or dendritic cells within the humoral and cellular immune defences against viruses and bacteria.
After expression, the 8F4 molecule has in vitro a strong costimulatory effect on various functions of T lymphocytes: 1. Marked enhancement of the proliferation of T lymphocytes.
2. Marked enhancement of the synthesis of certain cytokines by T lymphocytes.
3. Greatly increased expression of control molecules, for example surface molecules and cytokines, on and in T lymphocytes.
4. Marked improvement in T-cell-induced antibody formation (IgM and IgG) by B cells.
A 0 -1 ,0 f 7 The present invention furthermore provides a polypeptide having the biological activity of costimulation of T cells and having an amino acid sequence which shows at least 40% homology with the sequence comprising 199 amino acids in Fig. 15 (SEQ ID NO:2), or a biologically active fragment or an analogue thereof. A biologically active fragment or analogue is a fragment or analogue which likewise shows a costimulatory effect on T-cell lymphocytes or at least displays a biological effect of the nature of a blockage. Preference is given to a polypeptide or a biologically active fragment or analogue thereof which shows at least 60% homology with the sequence comprising 199 amino acids in Fig. 15 (SEQ ID NO:2). In a particularly preferred embodiment, the polypeptide according to the invention comprises an amino acid sequence which shows at least 80% homology with the sequence comprising 199 amino acids in Fig. 15 (SEQ ID NO:2), or a biologically active fragment or analogue thereof.
A particularly preferred polypeptide has the biological activity of costimulation of T cells and comprises an amino acid sequence as shown in Fig. (SEQ ID NO:2), or a biologically active fragment or an analogue thereof.
The invention includes allelic variants, fragments and analogues of the 8F4 molecule. These variants include naturally occurring allelic variants, substitution analogues in which one or more amino acids have been substituted by different amino acids, substitution analogues in which one or more amino acids have been substituted by different amino acids, deletion analogues in which one or more amino acids have been deleted and addition analogues in which one or more amino acids have been added. Deletion and addition of one or more amino acids may be done either 0' d_ ~1W 8 0 at an internal region of the polypeptide or at the amino or carboxyl terminus.
Polypeptides according to the invention fused to heterologous polypeptides are likewise embraced.
In another embodiment, the invention relates to DNA sequences which encode a polypeptide according to the invention or a biologically active fragment or 00 analogue thereof.
Mc These DNA sequences include the sequence shown in SEQ ID NO:1 (Fig. 16) as well as allelic variants, Sfragments, and analogues having biological activity.
C A preferred DNA sequence encodes a polypeptide having the biological activity of costimulation of T cells, the sequence being selected from the group consisting of: a) the DNA sequence shown in SEQ ID NO:1 (Fig. 16) and its complementary strand b) DNA sequence hybridizing with the sequences in (a) and c) DNA sequences which, because of the degeneracy of the genetic code, hybridize with the sequences in (a) and The aforementioned DNA sequences preferably hybridize together under stringent conditions.
Also provided are vectors which comprise these DNA sequences, and host cells which are transformed or transfected with these vectors.
In another embodiment, the invention relates to monoclonal antibodies against the 8F4 molecule. Accordingly, there is provided a mouse antibody which specifically recognizes a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation ofT lymphocytes, b) occurs on activated human CD4 and CD8 T lymphocytes but not resting or activated B lymphocytes, granulocytes, monocytes, NK cells or dendritic cells, 0 c) has two polypeptide chains, the said molecule having a molecular weight CN of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel Selectrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide 0 5 gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T 00 MC lymphocytes; ¢C wherein the mouse antibody recognizes 2 signal-activated but not resting T ("1 O 10 lymphocytes, and N wherein the mouse antibody, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates human T lymphocytes.
The monoclonal antibodies according to the invention can be prepared in a conventional way by the method described by Milstein and K6hler, Nature 256 (1975), 495-497. In particular, the monoclonal antibodies according to the invention can be prepared by immunizing mice with T cells which have been activated in vitro with phorbol myristate acetate (PMA) and ionomycin ("2-signal system") for 24 h. The spleen cells of the immunized mice are fused with myeloma cells. 8F4-specific 9 monoclonal antibodies are identified by their recognition of 2-signal-activated but not resting T lymphocytes. Moreover 8F4-specific antibodies do not stain T cells stimulated with one signal (either PMA or ionomycin) in a detection method carried out in a conventional way. 8F4-specific antibodies produce a typical staining pattern of tonsillar T cells and recognize an antigen of about 55 to 60 kDa in a nonreducing SDS-PAGE and of about 27 kDa and about 29 kDa in a reducing SDS-PAGE on activated T lymphocytes.
In another embodiment, the invention relates to hybridoma cells which produce the monoclonal antibodies according to the invention.
In another embodiment, the invention relates to the use of substances which inhibit the biological activity of the polypeptide 8F4 according to the invention as pharmaceuticals. The use of the monoclonal antibodies according to the invention, natural or synthetic ligands, agonists or antagonists of the 8F4 molecule is particularly preferred. These substances can be used as pharmaceuticals for the prevention or therapy of disorders in which the immune system is involved, in particular for the treatment or autoimmune diseases or for prevention of rejection reactions in organ transplants. Blockade of the interaction of the 8F4 antigen with its receptor improves, for example, the prevention of organ rejection because such a blockade affects only previously activated T lymphocytes. Another embodiment of the invention relates to the use of the polypeptide according to the invention as pharmaceutical. The polypeptide according to the invention can be used in particular for the prevention or therapy of disorders in which the immune system is involved, in particular for the treatment of cancers, AIDS, asthmatic disorders or chronic viral diseases such as HCV or HBV infections.
-n i 10 The polypeptide according to the invention can likewise be introduced into cells in a conventional way so that these cells for example constitutively express the polypeptide. For example, the nucleic acid sequence encoding the polypeptide or a vector comprising the nucleic acid sequencing encoding the polypeptide, for example the cDNA or genomic DNA, promoters, enhancers and other elements required for expression of the nucleic acid sequence can be inserted into a cell. The 8F4 cDNA (2641 nucleotides) depicted in Fig. 16 (SEQ ID NO:1) or fragments or derivatives thereof, is preferably employed for expression of the polypeptide according to the invention or fragments thereof.
The polypeptide according to the invention can also be introduced for example by means of liposomes into cells which then form the polypeptide on their cell surface. These cells can be used as pharmaceuticals according to the invention, in particular for restoring correct regulation of the human immune system, as occurs within the framework of numerous chronic infectious diseases, for example within the framework of AIDS, asthmatic disorders or in chronic viral hepatitis (for example HCV, HBV), or for stimulating the immune system in vitro or in vivo such as, for example, be used for the therapy of cancers.
In another embodiment, substances which specifically recognize the polypeptide according to the invention are used for diagnosing disorders in which the immune system is involved, the substances embracing in particular a monoclonal antibody, natural or synthetic ligands, agonists or antagonists. It is possible to use for the diagnosis for example an ELISA detection, flow cytometry, Western blot, radioimmunoassay, nephelometry or a histochemical staining.
The substances which recognize the polypeptide according to the invention also comprise nucleic acid sequences, the latter preferably being employed for
I
.<^dM 11 hybridization and/or nucleic acid (RNA, DNA) amplification (for example PCR).
In another embodiment, the invention relates to substances which have a positive or negative effect on (modulate) the signal transduction pathway of the polypeptide according to the invention into the T cell, and to the use of these substances as pharmaceuticals.
In another embodiment, the invention relates to substances which prevent up-regulation of the polypeptide according to the invention on the T-cell surface, and to the use thereof as pharmaceuticals.
In another embodiment, the polypeptide according to the invention or fragments thereof is expressed by a transgenic animal.
In another embodiment, the invention embraces a transgenic animal in which the gene which codes for the polypeptide according to the invention has been switched off ("knock-out").
The figures serve to illustrate the invention: Fig. 1 shows the result of an immunoprecipitation of the 8F4 antigen from activated human T cells. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE; 12% polyacrylamide gel (PAA gel)) reducing, SDS-PAGE (10% PAA gel) non-reducing. The conditions for elution of the antigen from the 8F4 matrix are indicated. "SDS" means sodium dodecyl sulphate; "DTT" means dithiothreitol, "Mr" means molecular weight and "kDa" means kilodalton.
Fig. 2a shows the result of a flow cytometry after induction of the 8F4 antigen on CD4' T cells. The activation time for the T cells is indicated in parentheses. "PMA" means phorbol myristate acetate; "PHA" means phytohaemagglutinin; "OKT3" is a monoclonal antibody against CD3; "MLR" means mixed lymphocyte reaction; "mAK 9.3" is a monoclonal antibody against CD28; "SEB" means staphylococcal enterotoxin B.
12 Fig. 2b shows the result for the kinetics of induction of the 8F4 antigen on CD4* T cells after activation with PMA and ionomycin in a flow cytometry.
The immunofluorescence (log) is plotted against the cell count.
Fig. 3 shows the result of a flow cytometry for identifying molecules which are involved in the induction of 8F4 in the mixed lymphocyte reaction.
"bio" means biotinylated antibody.
Fig. 4 shows the result of a histochemical investigation for localization of 8F4-positive cells in the tonsil.
Fig. 5 shows the result of an expression analysis of 8F4 on T and B cells from human tonsils in a flow cytometry. "bioPE" means biotinylated antibody and streptavidin-phycoerythrin secondary reagent.
Fig. 6 shows the coexpression of the 8F4 molecule with other activation markers (CD69, CD45) in a flow cytometry.
Fig. 7 shows diagrammatically the enhanced expression of activation molecules on T lymphocytes after costimulation by 8F4. Open circles represent 8F4 antibodies; triangles represent nonspecific antibodies of the same isotype; filled circles represent anti-CD28 antibodies-9.3.
Fig. 8 shows a diagrammatic comparison of the costimulating effect of 8F4 with the costimulating effect of CD28. "mAk" means monoclonal antibodies; "ATAC" means "activation induced T-cell-derived and chemokine-related"; "cpm" means radioactive disintegrations per minute.
Fig. 9 shows diagrammatically the enhancement of the synthesis of the antibodies of the IgM and IgG types by B cells after costimulation of T cells. "ng" means nanogram; "ml" means millilitre; "mAk" means monoclonal antibody.
13 Fig. 10 shows diagrammatically the prevention of the activation-induced apoptosis of peripheral T cells after costimulation by 8F4.
Fig. 11 shows expression of the 8F4 antigen on the MOLT-4V cell line. MOLT-4V cells were stained with a fluorescein-labelled 8F4 antibody (8F4-FITC) and investigated in flow cytometry (unfilled line, comparing with an isotype control (filled line)).
Fig. 12 shows the two-dimensional gel electrophoresis. A MOLT-4V cell lysate from 300x106 cells was immunoprecipitated as described. The eluate was fractionated on a non-reducing SDS-PAGE (10% PAA), and the region around 60 kDa was cut out of the gel. To reduce the disulphide bridges in the 8F4 molecule, the piece of gel was incubated in 5.3 M urea, 0.5 M Tris, pH 8.0, 1% SDS, 1% 6-mercaptoethanol at 500C for 1 h, and the free cysteine residues in the molecule were alkylated with 10 mM iodoacetamide (Sigma, Deisenhofen) (37°C, 30 min). The piece of gel was equilibrated in IxSDS-PAGE sample buffer for a further 30 min and mounted on a 12% PAA-SDS gel (with stacking gel). After fractionation by electrophoresis, the gel underwent silver staining. The location of the 8F4 protein was determined by surface iodination (cf. Fig. 1) and is marked by a circle. (All the procedures not described in detail were carried out by standard methods, see, for example, Westermeier, Electrophoresis in Practice, VCH Verlagsgesellschaft, Weinheim, 1997).
Fig. 13 shows a hybridization with Oligo 1 (SEQ ID NO:3). Lambda clones immobilized on nitrocellulose filters were hybridized with Oligo 1 as described in the examples. Exposure on an X-ray film is depicted (detail).
Fig. 14 shows a Northern blot analysis with the 8F4 cDNA. Hybridization of a Northern blot with the 8F4 cDNA produces a band which migrates in the gel between the 18S and 28S RNA. Fig. 14A shows the 14 behaviour as 2-signal-dependent (see above) activation antigen: no expression in resting lymphoid cells (PBL), strong expression in PMA+ionomycin-activated CD4+ T cells and distinctly reduced expression with PMA or ionomycin alone. Fig. 14B shows the strength of mRNA expression after different stimulation times (T cells (purified via nylon wool adherence, NTC), stimulated with PMA+ionomycin). Besides this the MOLT-4 cell lines (ATCC CRL-1582) which shows only minimal expression, and on the far right the MOLT-4V which was used for the cloning and which shows a distinct signal. Also loaded is the RNA from other cell lines on which no 8F4 expression was detectable in the analysis by flow cytometry: CEM (ATCC CCL-119), HUT-102 (ATCC TIB-162), HUT-78 (ATCC TIB-161), Jurkat (ATCC TIB-152), (Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) ACC83), Karpas 299 (Fischer, P. et al. (1988), Blood, 72:234-240), DEL (Barbey, S. et al. (1990), Int.
J. Cancer, 45:546-553).
Fig. 15 shows the amino acid sequence of the polypeptide 8F4 (SEQ ID NO:2).
Fig. 16 shows the 8F4 cDNA (SEQ ID NO:1).
The following examples illustrate the invention and are not to be understood restrictively.
Example 1: Generation of the 8F4 antibody Balb/c mice were immunized with human T cells which had previously been activated for 24 h with 33 ng/ml of the phorbol ester phorbol myristate acetate (PMA) (Sigma, Deisenhofen) and with 200 ng/ml of the Ca 2 ionophore ionomycin (Sigma, Deisenhofen) (so-called "2-signal activation"). After boosting three times, the spleen cells of the mice were fused with the myeloma P3X63Ag8.653 (ATCC No. CRL-1580), and antibodysecreting hybridomas were generated by standard methods; cf. Peters and Baumgarten, Monoclonal o <47 o 15 Antibodies, Springer, Heidelberg, 1992. The resulting antibodies were screened for activated versus resting T cells in flow cytometry. Activated ("2-signal activation") and resting T cells were incubated with the hybridoma supernatant and then labelled with a fluorescence-labelled secondary antibody; cf. Shapiro, Practical Flow Cytometry, Wiley-Liss, New York, 1995.
Only the antibodies which recognize molecules which were induced exclusively by PMA and the Ca 2 ionophore ionomycin on the T-cell surface, but not by one of the agents alone ("2-signal molecules"), were selected for further purification. The resulting antibodies were investigated in flow cytometry for similarity to or difference from known antibodies against activation molecules (cf. Table 1) on T cells. The criteria for this were, besides the abovementioned "2-signal dependence", the kinetics of induction on stimulated T cells and the expression on various cell lines.
Example 2: Immunoprecipitation of the 8F4 antigen Surface molecules from activated human T cells were iodinated with 125I by standard methods and immunoprecipitated with the antibody 8F4 by standard methods; cf. Goding, Monoclonal Antibodies: Principle and Practice, Academic Press, London, 1996. The antibody for the immunoprecipitation was coupled by the method of Schneider et al., Journal of Biological Chemistry 257 (1982), 10766-10769, to protein G (Pharmacia, Freiburg) (8F4 matrix). The matrix was washed as described by Schneider et al., see above. The immunoprecipitated 8F4 molecule was analysed for its molecular mass in an SDS-PAGE (non-reduced and reduced) in a conventional way; Goding, see above.
U)
16 Example 3: Flow cytometry The 8F4-carrying T cells were analysed in flow cytometry by standard methods; cf. Shapiro, Practical Flow Cytometry, Wiley-Liss, New York, 1995.
Exemplary embodiment 3.1: Flow cytometry after induction of the 8F4 antigen on CD4* T cells.
CD4 T cells from peripheral blood were stimulated with various agents in a conventional way, and investigated for expression of the 8F4 molecule in flow cytometry by a conventional method. The activation time for the T cells was between 24 hours and 144 hours with the various agents. Modes of activation: phorbol myristate acetate (PMA; 33 ng/ml), ionomycin (200 ng/ml), phytohaemagglutinin (PHA 1.5 mg/ml), OKT3 (monoclonal antibody against CD3), mixed lymphocyte reaction (MLR, between 50,000 CD4' T cells and 100,000 B cells), mAk 9.3 (monoclonal antibody against CD28), staphylococcal enterotoxin B (SEB, 0.1 ng/ml). Analysis revealed that various stimuli are suitable for inducing the 8F4 molecule on T cells, but the expression density differs. The most potent stimuli, besides the highly active pharmacological agents PMA and ionomycin, are those which represent a costimulatory situation such as, for example, accessory cells in the MLR or the costimulating mAk 9.3.
Exemplary embodiment 3.2: Kinetics of induction of the 8F4 antigen on CD4* T cells after activation with PMA and ionomycin.
CD4 T cells from peripheral blood were stimulated with PMA (33 ng/ml) and ionomycin (200 ng/ml) in a conventional way and investigated after 0, 4, 8, 12, 24 and 48 hours for expression of the 8F4 molecule by flow cytometry in a conventional way. The molecule is detectable on the surface after only four hours, and thus belongs to the class of 17 relatively early activation antigens. There is still good expression of the antigen even after 48 hours.
Exemplary embodiment 3.3: Flow cytometry to identify molecules which are involved in the induction of 8F4 in the "mixed lymphocyte reaction".
50,000 CD4+ T cells from peripheral blood were cocultivated with 100,000 allogeneic tonsillar B cells for 6 days (37 0 C, 5.2% CO2, 200 p1 of RPMI 1640 with FCS in 96-well round-bottom plates) and then investigated for expression of the 8F4 molecule in flow cytometry. At the start of cultivation, various antibodies (anti-CD80, anti-CD86, anti-MHCII; all mg/ml) were added to the culture in order to examine the dependence of 8F4 induction on these molecules.
Expression of 8F4 can be blocked only by blockade of the CD86/CD28 interaction, but not by blockade of The blockade effect in this case is even stronger than the blockade of MHCII (positive control).
Exemplary embodiment 3.4: Expression of 8F4 on T and B cells from human tonsils.
B cells and T cells from tonsillar tissue from various sources were purified in a conventional way and investigated by flow cytometry for expression of the 8F4 molecule. Whereas the signal was not unambiguously significant on B cells, there was expression of the 8F4 molecule in varying density by about 50-80% of tonsillar T cells. It is possible in this case to identify two populations differing in the level of fluorescence (8F4 high and low, respectively), and differing in expression on the various tonsils. Thus, for example, tonsils shows a pronounced 8F4 low population and other tonsils shows a pronounced 8F4 high population.
Exemplary embodiment 3.5: Coexpression of the 8F4 molecule with other activation markers.
,7 18 T cells purified from human tonsils were analysed in 2-colour flow cytometry for coexpression of the 8F4 molecule with other activation markers. In tonsils, 8F4 is coexpressed with CD69 as well as with variants of the CD45 molecule. In this case, the 8F4 high cells are unambiguously correlated with a CD45RO expression, while the 8F4-negative cells carry the phenotype CD45RA is mainly expressed by so-called "naive" T cells, whereas CD45RO is associated with an effector cell function. The 8F4* cells are thus mainly "mature" T cells. CD45RO and CD45RA are isoforms of Example 4: Localization of 8F4-positive cells in the tonsil Tonsillar tissue in frozen sections was stained with the 8F4 antibody in the APAAP technique (alkaline phosphatase-anti-alkaline phosphatase) by standard methods. 8F4 cells were found preferentially in the germinal centre of the tonsils, but also in part in the T-cell zone of the tonsils.
Example 5: Costimulation of T lymphocytes 96-well plates were coated with a goat antimouse Ig antibody (20 pg/ml), washed, and loaded with the anti-CD3 monoclonal antibody OKT3 (various dilutions of an ascites) and the 8F4 antibody according to the invention (2 jig/ml). The OKM1 antibody or the 2A11 antibody (both 2 pg/ml) were used as isotype control.
Exemplary embodiment 5.1: Enhanced expression of activation molecules on T lymphocytes after costimulation by 8F4.
Purified CD4" T cells from peripheral blood were activated with various concentrations of the monoclonal antibody OKT3 and, at the same time., costimulated with the 8F4 antibody or a nonspecific antibody of the same isotype. As comparison, costimulation was carried out .4 C 19 with the anti-CD28 antibody-9.3, one of the strongest known costimulatory antibodies. Even with optimal stimulation by CD3, a costimulatory effect is still to be seen both with the mAk 8F4 and with the mAk 9.3. In the suboptimal OKT3 region, that is to say the region in which complete T-cell activation cannot be achieved without costimulation, both antibodies are able to increase the expression of other activation antigens by a factor of 4 to 100, and the effect of the anti-CD28 antibody is still visible even at very high OKT3 dilutions. This is attributable to the fact that with very weak OKT3 stimulation the 8F4 antigen is no longer brought to the cell surface and thus cannot be crosslinked by the mAk 8F4 either.
Exemplary embodiment 5.2: Comparison of the costimulating effect of 8F4 with the costimulating effect of CD28.
Purified CD8* T cells were stimulated with a suboptimal concentration of the monoclonal antibody OKT3 for 51 h. The costimulators employed were antibody 8F4, antibody 9.3 (anti-CD28) and isotype controls (2 Ag/ml each). After completion of the stimulation time, the T-cell proliferation rate was determined by 3 H-thymidine incorporation. In parallel cultures, the supernatant was removed and the concentration of the cytokines ATAC/lymphotactin and IL-2 was determined.
8F4 and CD28 differ greatly from one another in relation to IL-2 synthesis. CD28 costimulation leads, as also described in the prior art (Chambers and Allison, Current Opinion in Immunology 9 (1997), 396- 404), to very extensive IL-2 secretion. By contrast, IL-2 production with 8F4 is below the detection limit.
However, proliferation is comparable in the two mixtures, and thus the autocrine growth of the T cells must be attributed to other factors on costimulation of 8F4. The two antibodies also differ scarcely at all in 20 the costimulatory effect in relation to secretion of the lymphokine ATAC.
Example 6: Determination of the immunoglobulins synthesized by B cells after interaction with 8F4costimulated T cells 96-well plates were coated with a goat antimouse Ig antibody (20 ig/ml), and loaded with the anti- CD3 monoclonal antibody OKT 3 (1:500 to 1:80,000 ascites) and the 8F4 antibody according to the invention (2 ug/ml). The OKM1 antibody or the 2A11 antibody was used as isotype control. In some experiments, a costimulation was carried out with a CD28-specific antibody for comparison; cf. Hara et al., Journal of Experimental Medicine 161 (1985), 1513-1524. 50,000 purified (Magnetobeads, Dynal, Hamburg) CD4" T cells purity) from peripheral blood and 25,000 allogenic tonsillar B cells (negative selection by T-cell rosetting with sheep erythrocytes, 96% purity) were pipetted into each well of the culture plates pretreated in this way, and cocultivated for 8 days. After this period, the supernatant was removed and analysed for the concentration of secrete immunoglobulins of the IgM and IgG types in an ELISA in a conventional way; cf. Nishioka and Lipsky, Journal of Immunology 153 (1994), 1027-1036.
Exemplary embodiment 6.1: Enhancement of the synthesis of antibodies of the IgM and IgG types by the B cells after costimulation of T cells.
Purified CD4* T cells from peripheral blood were cocultivated with allogeneic B cells from tonsils for 8 days in a conventional way. With suboptimal stimulation of the T cells with the OKT3 antibody, the costimulation of the T cells by 8F4 enhances the secretion of IgM and IgG immunoglobulins by a factor of 21 Example 7: Prevention of the activation-induced apoptosis of peripheral T cells after costimulation by 8F4.
Peripheral T cells (purified by nylon wool adherence in a conventional way), were stimulated with PHA (1.5 mg/ml) for 20 h and cultivated with IL-2 for 6 days. The cells were then restimulated by OKT3 with and without costimulation by mAk 8F4 (2 g/ml). The apoptosis was determined by staining the DNA with propidium iodide in flow cytometry (FACS). With suboptimal stimulation via the T-cell receptor complex, costimulation by 8F4 can reduce the proportion of apoptotic cells by a factor of 4.
Example 8: Cloning of the cDNA coding for the 8F4 protein A cell line (MOLT-4V) which expresses the 8F4 antigen constitutively was identified in flow cytometry by staining with a fluorescent dye-coupled 8F4 antibody (Fig. 11). The MOLT-4V line is a variant of the human T-cell line MOLT-4 (American Type Culture Collection (ATCC) CRL-1582).
This cell line was used for preparative purification of the 8F4 antigen with the aid of the monoclonal antibody: The cells were cultivated on a large scale (150 1) in roller culture bottles and removed by centrifugation, and the cellular proteins were extracted using a lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF (Sigma, Deisenhofen), 1% NP-40 (Boehringer, Mannheim)). Cell nuclei and other insoluble constituents were removed by ultracentrifugation. The cell lysate obtained in this way was preincubated with Sepharose CL4-B (Pharmacia, Freiburg) for 2 h in order to remove proteins which bind nonspecifically to Sepharose. Incubation then took place with the 8F4 0 n, r1 22 immunoaffinity matrix described in Example 2 above (4 h at 4 0 The matrix was packed into a column and then washed several times under conditions with which there is exclusive removal of nonspecifically binding proteins (1.50 mM Tris, pH 8.0, 300 mM NaC1, 1 mM EDTA, 1 mM PMSF, 0.5% NP-40; 2.50 mM Tris, pH 8.0, 150 mM NaC1, 1 mM EDTA, 1 mM PMSF, 0.5% NP-40, 0.1% SDS; 3.
0.2 M glycine pH 4.0, 0.5% CHAPS (Merck, Darmstadt)).
The 8F4 antigen was eluted from the matrix with 0.2 M glycine, pH 2.5, 0.5% CHAPS. The eluate was concentrated by ultrafiltration (Amicon Centricon Millipore, Eschborn).
In order to achieve further purification of the 8F4 molecule, the dimeric structure of the molecule (see Fig. 1) was utilized in a two-dimensional gel electrophoresis (nonreducing/reducing): since most proteins occur as monomer, they migrate on a diagonal in gel electrophoresis, whereas the 8F4 molecule migrates at 55-60 kDa in the 1st dimension (nonreducing) and at 27 and 29 kDa (Fig. 12) in the 2nd dimension (reducing).
For preparative fractionation, the immunoprecipitates from in each case 20x10 9 cells were prepared as described above for Fig. 12 and fractionated in two-dimensional gel electrophoresis, the gel was stained with Coomassie blue G250 (Biorad, Munich) and the areas indicated in Fig. 12 were separately cut out of the gel (8F4-27 kDa and 8F4- 29 kDa respectively).
For peptide microsequencing, the proteins from in each case 4 pieces of gel were digested with trypsin and eluted from the gel. The tryptic fragments were fractionated by HPLC and individual fractions were subjected to Edman degradation (method described in detail in Groettrup, M. et al. (1996), Eur. J.
Immunol., 26:863-869).
23 Sequencing of the 8F4-29 kDa sample revealed, besides fragments of known proteins, a peptide sequence XRLTDVT for which no human correlate was found in any of the protein databases.
Unambiguous translation back of a protein sequence into a DNA sequence is not possible. Thus, translation of the above peptide sequence back into an oligonucleotide with 17 nucleotides results in 2048 permutations. However, a specific method (Wozney, J.M. (1990), Methods Enzymol. 182:738-751) makes it possible to screen a cDNA bank with degenate oligonucleotides. On the basis of the peptide sequence found, 2 oligonucleotides (Oligo 1 (SEQ ID NO:3); MGN CTS ACN GAY GTN AC, 512 permutations; Oligo 2 (SEQ ID NO:4): MGN YTD ACN GAY GTN AC, 1024 permutations) were synthesized.
For screening, a cDNA bank was constructed from the MOLT-4V cell line also used for the protein purification: Complete RNA was isolated by the guanidinium/CsCl method (Chirgwin, J.M. et al. (1979), Biochemistry 18:5294-5299), and mRNA was concentrated on Oligo-dTcellulose columns (Gibco BRL, Eggenstein). Synthesis of the first and second cDNA strands was carried out using a commercial cDNA synthesis system (Gibco BRL, Eggenstein) using Oligo-dT primers in accordance with the manufacturer's instructions. The cDNA was was ligated via EcoRI adaptors into the Lambda ZAPII vector (Stratagene, Heidelberg).
The cDNA bank was plated out by standard methods (Vogeli, G. and Kaytes, P.S. (1987), Methods Enzymol., 152:407-515) and the Lambda DNA was immobilized on nitrocellulose filters (Optitran BA-S Schleicher Schuell, Dassel).
24 The abovementioned oligonucleotides were radiolabelled using T4 polynucleotide kinase (NEBL, Schwalbach) and y- 32 P ATP (NEN Du Pont, Brussels) (Wallace, R.B. and Miyada, C.G. (1987), Methods Enzymol., 152:432-442).
Hybridization of the filters took place in a buffer described for degenerate oligonucleotides (Wozney, J.M. (1990), Methods Enzymol. 182:738-751) with 3 M tetramethylammonium chloride (Roth, Karlsruhe) at 48 0 C. The filters were washed as described in the abovementioned reference, the washing temperature being 0 C. Exposure of these filters on an X-ray film revealed about 50 positive clones per 100,000 plated phages (Fig. 13).
6 clones were further characterized by transferring them by in vivo excision, using the method described by the manufacturer of the vector (Stratagene, Heidelberg), into a plasmid vector, and partially sequencing with T3 and T7 primers (BigDye Terminator Cycle Sequencing Kit, Applied Biosystems, Foster City, USA). One of the clones contained a sequence which on translation provided exactly the peptide sequence which was sought. This clone was used for hybridization of a Northern blot (Fig. 14) (Kroczek, R.A. (1993), J. Chromatogr., 618, 133-145).
The expression pattern of the mRNA corresponded exactly to the expression of the 8F4 molecule as was known from investigations on the monoclonal antibody by flow cytometry. Since the clone which was found contained only the 3' end of the cDNA sought, a fragment on the side was used to isolate the complete 8F4 cDNA.
Several clones were sequenced on both strands.
The 8F4 cDNA (2641 nucleotides) is depicted in Fig. 16 and in the sequence listing under SEQ ID NO:1, and codes for a protein having 199 amino acids (Nucleotides 68-664), depicted in Fig. 15 and in the sequence listing under SEQ ID NO:2. Sequencing of several independent clones f rom the cDNA bank showed some deviations from the sequence shown here, but these are all in the 31-untranslated region: Pos. 909-910:deletion Pos. 1631:T->C Pos. 2074:G->T Pos. 2440:G->C Pos. 2633: alternative polyadenylation site 26- Table 1: Table 1 summarizes the antibodies used (clone) their source of origin (source), the specificity for their particular antigen (specificity) and, where appropriate, their labelling (label).
Speci- Label Isotype Clone Source f ic ity CD3 Cy-Chrome IgGi UCHT1 Pharmingen, Hamburg CD3 -IgG2a OKT3 ATCC CRL-8001 CD~lb -IgG2b OKMl ATCC CRL-8026 FITC IgG2a B1.49.9 Immunotech, Hamburg CD28 -IgG2a 9.3 Immunex Corp., Seattle Cy-Chrome IgG2b HI100 Pharmingen, Hamburg FITC IgG2a UCHLI Immunotech, Hamburg CD69 FITC IgGi FN5O Pharmingen, Hamburg IgGl L307.4 Becton Dickinson, Heidelberg CD86 -IgG2b 1T2.2 Pharmingen, Hamburg CD154 FITC IgG1 TRAP-i Hybridomal MHCII -IgG2a L243 ATCC BF4 -IgG1 8F4 Hybridoma' BF4 Biotin IgG1 8F4 Hybridomal Isotype IgG1 2A12. Hybridomal 2 IgGl Isotype FITC IgGl 2A11 Hybridornal 2 IgGl Isotype Biotin IgGl ASA-l Hybridoma' IgGI.
d,1c 27 1 The hybridoma cell line was generated in a conventional way, and the antibody was purified and labelled where appropriate.
2 Directed against a synthetic peptide The antisera and secondary reagents used in the examples were purchased from: goat anti-mouse Ig, FITC conjugated, from Jackson Immuno Research Lab., USA; Streptavidin, PE-conjugated, from Jackson Immuno Research Lab., USA; rabbit anti-mouse Ig fraction, from Sigma, Deisenhofen.
Claims (72)
1. A mouse antibody which specifically recognizes a human 8F4 polypeptide, wherein said human 8F4 polypeptide: Sa) has the biological activity of costimulation of T lymphocytes, b) occurs on activated human CD4 and CD8' T lymphocytes but not resting or activated B lymphocytes, granulocytes, monocytes, NK cells or 00 m dendritic cells, ¢n c) has two polypeptide chains, the said molecule having a molecular 0weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide N 10 gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; wherein the mouse antibody recognizes 2 signal-activated but not resting T lymphocytes, and wherein the mouse antibody, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates human T lymphocytes.
2. The mouse antibody of claim 1 which is a monoclonal antibody.
3. The mouse monoclonal antibody of claim 1, wherein said mouse monoclonal antibody recognizes the human 8F4 polypeptide of about kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE.
4. The mouse monoclonal antibody of claim 2, wherein said mouse monoclonal antibody recognizes the peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE. The mouse monoclonal antibody of claim 2, wherein said mouse monoclonal antibody recognizes the peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE. O 6. The mouse monoclonal antibody of claim 2, wherein said mouse N monoclonal antibody recognizes a human 8F4 polypeptide present on activated 1 human CD4' T lymphocytes and activated human CD8' T lymphocytes.
7. A mouse antibody which specifically recognizes a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, oO 0M b) occurs on activated human CD4 and CD8 T lymphocytes but not CN n resting or activated B lymphocytes, granulocytes, monocytes, NK cells or 0dendritic cells, N 10 c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; wherein the mouse antibody recognizes 2 signal-activated but not resting T lymphocytes, and wherein the mouse antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide.
8. The mouse antibody of claim 7 which is a monoclonal antibody.
9. A hybridoma that produces a mouse monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, b) occurs on activated human CD4 and CD8 T lymphocytes but not resting or activated B lymphocytes, granulocytes, monocytes, NK cells or dendritic cells, c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide O gel electrophoresis, and the two polypeptide chains of the said molecule having a C molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS Spolyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID 0 5 NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; 0and wherein the hybridoma produces a mouse monoclonal antibody that, 00 m in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates m proliferation of human T lymphocytes. N 10 10. The hybridoma of claim 9, wherein said hybridoma produces a mouse monoclonal antibody that recognizes the human 8F4 polypeptide of about kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE.
11. The hybridoma of claim 9, wherein said hybridoma produces a mouse monoclonal antibody that recognizes the peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE.
12. The hybridoma of claim 9, wherein said hybridoma produces a mouse monoclonal antibody that recognizes the peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE.
13. The hybridoma of claim 9, wherein said hybridoma produces a mouse monoclonal antibody that recognizes a human 8F4 polypeptide present on activated human CD4' T lymphocytes and activated human CD8' T lymphocytes.
14. A hybridoma that produces a mouse monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, b) occurs on activated human CD4 and CD8 T lymphocytes but not resting or activated B lymphocytes, granulocytes, monocytes, NK cells or dendritic cells, c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide O gel electrophoresis, and the two polypeptide chains of the said molecule having a c molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS C polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; O wherein the mouse monoclonal antibody recognizes 2 signal-activated but 00 c not resting T lymphocytes; 0 wherein the mouse monoclonal antibody, in conjunction with anti-CD3 O 10 monoclonal antibody OKT3, costimulates proliferation of human T lymphocytes; c and wherein the mouse monoclonal antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide. A pharmaceutical composition comprising a monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, b) occurs on activated human CD4 and CD8 T lymphocytes but not resting or activated B lymphocytes, granulocytes, monocytes, NK cells or dendritic cells, c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; wherein the monoclonal antibody recognizes 2 signal-activated but not resting T lymphocytes, and wherein the monoclonal antibody, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates human T lymphocytes. 0 16. A pharmaceutical composition comprising a monoclonal antibody that Cl recognizes a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, b) occurs on activated human CD4' and CD8 T lymphocytes but not 0 5 resting or activated B lymphocytes, granulocytes, monocytes, NK cells or dendritic cells, 0 c) has two polypeptide chains, the said molecule having a molecular oO M weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide Cc gel electrophoresis, and the two polypeptide chains of the said molecule having a 0 10 molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS c polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; wherein the monoclonal antibody recognizes 2 signal-activated but not resting T lymphocytes, wherein the monoclonal antibody, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates human T lymphocytes; and wherein the monoclonal antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide.
17. A method for producing the mouse monoclonal antibody of claim 2 or 8, comprising: culturing an antibody-secreting hybridoma obtained by: fusion of a myeloma cell line cell with a spleen cell of a mouse immunized with 2-signal-activated human CD4' T lymphocytes from human peripheral blood; and (ii) selection of a hybridoma that produces said antibody, such that the mouse monoclonal antibody is produced.
18. The mouse monoclonal antibody of claim 2 or 8, wherein said mouse monoclonal antibody recognizes the human 8F4 polypeptide of about kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE. O 19. The mouse monoclonal antibody of claim 2 or 8, wherein said mouse C1 monoclonal antibody recognizes the peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE. The mouse monoclonal antibody of claim 2 or 8, wherein said mouse monoclonal antibody recognizes the peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE. 00
21. The mouse monoclonal antibody of claim 2 or 8, wherein said mouse monoclonal antibody recognizes a human 8F4 polypeptide present on activated C human CD4 T lymphocytes and activated human CD8 T lymphocytes.
22. The hybridoma of claim 9 or 14, wherein said hybridoma produces a mouse monoclonal antibody that recognizes the human 8F4 polypeptide of about kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE.
23. The hybridoma of claim 9 or 14, wherein said hybridoma produces a mouse monoclonal antibody that recognizes the peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE.
24. The hybridoma of claim 9 or 14, wherein said hybridoma produces a mouse monoclonal antibody that recognizes the peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE. The hybridoma of claim 9 or 14, wherein said hybridoma produces a mouse monoclonal antibody that recognizes a human 8F4 polypeptide present on activated human CD4' T lymphocytes and activated human CD8 T lymphocytes.
26. The mouse monoclonal antibody of claim 8, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced T lymphocyte proliferation. O 27. The mouse monoclonal antibody of claim 8, wherein the mouse C1 monoclonal antibody inhibition of costimulation of T lymphocytes by the human a 8F4 polypeptide is exhibited as an inhibition of 8F4-induced ATAC expression. S28. The mouse monoclonal antibody of claim 8, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced CD25 expression. 00 (O
29. The mouse monoclonal antibody of claim 8, wherein the mouse Smonoclonal antibody inhibition of costimulation of T lymphocytes by the human c- 8F4 polypeptide is exhibited as an inhibition of 8F4-induced CD69 expression.
30. The mouse monoclonal antibody of claim 8, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced TRAP expression.
31. The mouse monoclonal antibody of claim 8, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of T lymphocyte induction of immunoglobulin production by B lymphocytes.
32. The mouse monoclonal antibody of claim 8, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of reduction of 8F4-induced apoptosis in activated T lymphocytes.
33. The hybridoma of claim 14, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced T lymphocyte proliferation.
34. The hybridoma of claim 14, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced ATAC expression. 0 35. The hybridoma of claim 14, wherein the mouse monoclonal antibody N inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is Sexhibited as an inhibition of 8F4-induced CD25 expression. 0 36. The hybridoma of claim 14, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced CD69 expression. oO C 37. The hybridoma of claim 14, wherein the mouse monoclonal antibody Sinhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is N exhibited as an inhibition of 8F4-induced TRAP expression.
38. The hybridoma of claim 14, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of T lymphocyte induction of immunoglobulin production by B lymphocytes.
39. The hybridoma of claim 14, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of reduction of 8F4-induced apoptosis in activated T lymphocytes. The pharmaceutical composition of claim 16, wherein the monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced T lymphocyte proliferation.
41. The pharmaceutical composition of claim 16, wherein the monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced ATAC expression.
42. The pharmaceutical composition of claim 16, wherein the monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced CD25 expression. 0 43. The pharmaceutical composition of claim 16, wherein the monoclonal N antibody inhibition of costimulation of T lymphocytes by the human 8F4 C polypeptide is exhibited as an inhibition of 8F4-induced CD69 expression. S44. The pharmaceutical composition of claim 16, wherein the monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced TRAP expression. 00 (No M 45. The pharmaceutical composition of claim 16, wherein the monoclonal (N 0 antibody inhibition of costimulation of T lymphocytes by the human 8F4 CN polypeptide is exhibited as an inhibition of T lymphocyte induction of immunoglobulin production by B lymphocytes.
46. The pharmaceutical composition of claim 16, wherein the monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of reduction of 8F4-induced apoptosis in activated T lymphocytes.
47. The mouse monoclonal antibody of claim 8, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of: 8F4-induced T lymphocyte proliferation, 8F4-induced ATAC expression, 8F4-induced CD25 expression, 8F4- induced CD69 expression, 8F4-induced TRAP expression, T lymphocyte induction of immunoglobulin production by B lymphocytes and reduction of 8F4- induced apoptosis in activated T lymphocytes.
48. The hybridoma of claim 14, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as exhibited as an inhibition of: 8F4-induced T lymphocyte proliferation, 8F4-induced ATAC expression, 8F4-induced CD25 expression, 8F4-induced CD69 expression., 8F4-induced TRAP expression, T lymphocyte induction of immunoglobulin production by B lymphocytes and reduction of 8F4-induced apoptosis in activated T lymphocytes. 0 49. The pharmaceutical composition of claim 16, wherein the monoclonal N antibody inhibition of costimulation of T lymphocytes by the human 8F4 q polypeptide is exhibited as an inhibition of: 8F4-induced T lymphocyte proliferation, 8F4-induced ATAC expression, 8F4-induced CD25 expression, 8F4- O 5 induced CD69 expression., 8F4-induced TRAP expression, T lymphocyte induction of immunoglobulin production by B lymphocytes and reduction of 8F4- induced apoptosis in activated T lymphocytes. oO Mn 50. The mouse monoclonal antibody of claim 2, wherein the costimulation of (N Sproliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of N 10 1:10,000.
51. The mouse monoclonal antibody of claim 2, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:5,000.
52. The mouse monoclonal antibody of claim 12, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:2,500.
53. The mouse monoclonal antibody of claim 1, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:1,000.
54. The mouse monoclonal antibody of claim 8, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:10,000. The mouse monoclonal antibody of claim 8, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:5,000. O 56. The mouse monoclonal antibody of claim 8, wherein the costimulation of C1 proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 0 1:2,500. 0 57. The mouse monoclonal antibody of claim 8, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:1,000. 00 oO
58. The hybridoma of claim 9, wherein the costimulation of proliferation of Shuman T lymphocytes is exhibited at a dilution of OKT-3 of 1:10,000. (N
59. The hybridoma of claim 9, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:5,000. The hybridoma of claim 9 wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:2,500.
61. The hybridoma of claim 9, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:1,000.
62. The hybridoma of claim 14, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:10,000.
63. The hybridoma of claim 14, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:5,000.
64. The hybridoma of claim 14, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:2,500. The hybridoma of claim 14, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:1,000. 0 66. The pharmaceutical composition of claim 15, wherein the costimulation of 0 N proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of S1:10,000. 0 67. The pharmaceutical composition of claim 15, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:5,000. 00 M 68. The pharmaceutical composition of claim 15, wherein the costimulation of a proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of c 1:2,500.
69. The pharmaceutical composition of claim 15, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:1,000. The pharmaceutical composition of claim 16, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:10,000.
71. The pharmaceutical composition of claim 16, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:5,000.
72. The pharmaceutical composition of claim 16, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:2,500.
73. The pharmaceutical composition of claim 16, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:1,000.
74. The pharmaceutical composition of claim 15, wherein the monoclonal antibody is a mouse monoclonal antibody. 0 75. The pharmaceutical composition of claim 16, wherein the monoclonal Cl antibody is a mouse monoclonal antibody. r 76. A method of inhibiting costimulation of human T lymphocytes comprising: ID Scontacting a human T lymphocyte with a monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, oo Mq b) occurs on activated human CD4 and CD8 T lymphocytes but not (N q resting or activated B lymphocytes, granulocytes, monocytes, NK cells or 0dendritic cells, N 10 c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; wherein the monoclonal antibody recognizes 2 signal-activated but not resting T lymphocytes; and wherein the monoclonal antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide, such that costimulation of the human T lymphocyte is inhibited.
77. The method of claim 76, wherein the monoclonal antibody recognizes the human 8F4 polypeptide of about 55 kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE.
78. The method of claim 76, wherein the monoclonal antibody recognizes the peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE.
79. The method of claim 76, wherein the monoclonal antibody recognizes the peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE. ID 0 80. The method of claim 76, wherein the monoclonal antibody recognizes a CI human 8F4 polypeptide present on human CD4' T lymphocytes and activated y human CD8' T lymphocytes. OD
81. A method of inhibiting rejection of an organ transplant, comprising: administering to an individual in need of such inhibition a monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said human 8F4 polypeptide: 00 M a) has the biological activity of costimulation of T lymphocytes, ¢n b) occurs on activated human CD4 and CD8 T lymphocytes but not 0resting or activated B lymphocytes, granulocytes, monocytes, NK cells or 1 10 dendritic cells, c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; wherein the monoclonal antibody recognizes 2 signal-activated but not resting T lymphocytes; and wherein the monoclonal antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide, in an amount sufficient to inhibit rejection of an organ transplant.
82. The method of claim 81, wherein the monoclonal antibody recognizes the human 8F4 polypeptide of about 55 kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE.
83. The method of claim 81, wherein the monoclonal antibody recognizes the peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE.
84. The method of claim 81, wherein the monoclonal antibody recognizes the peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE. O 85. The method of claim 81, wherein the monoclonal antibody recognizes a C human 8F4 polypeptide present on activated human CD4 T lymphocytes and C activated human CD8+ T lymphocytes. S86. A method for treating an immune disorder, comprising: administering to an individual in need of treatment a monoclonal antibody that recognizes a human S8F4 polypeptide, wherein said human 8F4 polypeptide: 00 M a) has the biological activity of costimulation of T lymphocytes, c b) occurs on activated human CD4' and CD8 T lymphocytes but not 0resting or activated B lymphocytes, granulocytes, monocytes, NK cells or c 10 dendritic cells, c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; wherein the monoclonal antibody recognizes 2 signal-activated but not resting T lymphocytes, in an amount sufficient to ameliorate a symptom of the immune disorder, such that the immune disorder is treated.
87. A method for treating an autoimmune disorder, comprising: administering to an individual in need of treatment a monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, b) occurs on activated human CD4' and CD8 T lymphocytes but not resting or activated B lymphocytes, granulocytes, monocytes, NK cells or dendritic cells, c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide 0 gel electrophoresis, and the two polypeptide chains of the said molecule having a N molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS q polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; wherein the monoclonal antibody recognizes 2 signal-activated but not 00 M resting T lymphocytes, c in an amount sufficient to ameliorate a symptom of the autoimmune 0 10 disorder, such that the autoimmune disorder is treated.
88. A method for treating cancer, comprising: administering to an individual in need of treatment a monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, b) occurs on activated human CD4' and CD8' T lymphocytes but not resting or activated B lymphocytes, granulocytes, monocytes, NK cells or dendritic cells, c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; wherein the monoclonal antibody recognizes 2 signal-activated but not resting T lymphocytes, in an amount sufficient to ameliorate a symptom of the cancer, such that the cancer is treated. O 89. A method for treating a chronic viral disease, comprising: administering to 1 an individual in need of treatment a monoclonal antibody that recognizes a y human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, O 5 b) occurs on activated human CD4 and CD8 T lymphocytes but not resting or activated B lymphocytes, granulocytes, monocytes, NK cells or 0 dendritic cells, oo M c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide 0 10 gel electrophoresis, and the two polypeptide chains of the said molecule having a C N molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; wherein the monoclonal antibody recognizes 2 signal-activated but not resting T lymphocytes, in an amount sufficient to ameliorate a symptom of the chronic viral disease, such that the chronic viral disease is treated.
90. A method for treating AIDS, comprising: administering to an individual in need of treatment a monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, b) occurs on activated human CD4' and CD8 T lymphocytes but not resting or activated B lymphocytes, granulocytes, monocytes, NK cells or dendritic cells, c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and 0 d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID c1 NO:2), or a biologically active fragment thereof showing likewise a costimulatory 0 effect on T lymphocytes; wherein the monoclonal antibody recognizes 2 signal-activated but not O 5 resting T lymphocytes, in an amount sufficient to ameliorate a symptom of AIDS, such that AIDS is treated. 00 (N c 91. A method for treating an asthmatic disorder, comprising: administering to 0 an individual in need of treatment a monoclonal antibody that recognizes a N 10 human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, b) occurs on activated human CD4' and CD8 T lymphocytes but not resting or activated B lymphocytes, granulocytes, monocytes, NK cells or dendritic cells, c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; wherein the monoclonal antibody recognizes 2 signal-activated but not resting T lymphocytes, in an amount sufficient to ameliorate a symptom of the asthmatic disorder, such that the asthmatic disorder is treated.
92. The method of claim 91, wherein the monoclonal antibody recognizes the human 8F4 polypeptide of about 55 kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE. 0 93. The method of claim 91, wherein the monoclonal antibody recognizes the N peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE. V 94. The method of claim 91, wherein the monoclonal antibody recognizes the 0 peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE.
95. The method of claim 91, wherein the monoclonal antibody recognizes a 00 human 8F4 polypeptide present on activated human CD4 T lymphocytes and Sactivated human CD8 4 T lymphocytes. S96. Use of a monoclonal antibody which specifically recognizes a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, b) occurs on activated human CD4' and CD8' T lymphocytes but not resting or activated B lymphocytes, granulocytes, monocytes, NK cells or dendritic cells, c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; wherein the monoclonal antibody recognizes 2 signal-activated but not resting T lymphocytes; and wherein the monoclonal antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide and/or, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates human T lymphocytes, for the production of pharmaceuticals.
97. The use according to claim 96 for the production of a pharmaceutical for the treatment of autoimmune diseases, for the prevention of rejection reactions in organ transplants and/or for the treatment of dysregulation of the immune system. 0 98. The use according to claim 97, wherein the autoimmune disease is C1 selected from rheumatoid arthritis, ankylosing spondylitis, Sj6gren's syndrome y and/or ulcerative colitis. ID 0 99. Use of a monoclonal antibody which specifically recognizes a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, 00 oO b) occurs on activated human CD4 and CD8 T lymphocytes but not m' resting or activated B lymphocytes, granulocytes, monocytes, NK cells or Sdendritic cells, N 10 c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; wherein the monoclonal antibody recognizes 2 signal-activated but not resting T lymphocytes, for the production of means for the diagnosis of disorders in which the immune system is involved.
100. The use of an antibody according to any one of claims 96-99, wherein the T lymphocytes are CD4' T lymphocytes.
101. The use of an antibody according to any one of claims 96-99, wherein the T lymphocytes are CD8 T lymphocytes.
102. The use according to any one of claims 96-101, wherein the monoclonal antibody recognizes an antigen of about 55 to 60 kDa in a non-reducing SDS- PAGE on activated T lymphocytes. 52 O 103. The use according to any one of claims 96-101, wherein the monoclonal l antibody recognizes an antigen of about 27 and about 29 kDa in a reducing SDS- SPAGE on activated T lymphocytes. 0 104. Use of a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, Sb) occurs on activated human CD4 and CD8' T lymphocytes but not 00 M resting or activated B lymphocytes, granulocytes, monocytes, NK cells or (N n dendritic cells, c) has two polypeptide chains, the said molecule having a molecular N 10 weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and d) comprises an amino-acid sequence which shows at least homology with the sequence comprising 199 amino acid in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes, or comprises the amino acid sequence shown in Fig. (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; for the production of pharmaceuticals for the treatment of cancers, Aids, asthmatic disorders and/or chronic viral diseases such as HCV or HBV infections.
105. Use of cells comprising a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, b) occurs on activated human CD4' and CD8 T lymphocytes but not resting or activated B lymphocytes, granulocytes, monocytes, NK cells or dendritic cells, c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a 0 molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS C1 polyacrylamide gel electrophoresis, and Sd) comprises an amino-acid sequence which shows at least Shomology with the sequence comprising 199 amino acid in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes, or comprises the amino acid sequence shown in Fig. OC\ (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a 00 c costimulatory effect on T lymphocytes; 0 for the production of pharmaceuticals. N 10 106. The use of cells according to claim 105 for the production of a pharmaceutical for the treatment of cancers, AIDS, asthmatic disorders and/or chronic viral diseases such as HCV or HBV infections.
107. The use according to claim 99, where an ELISA detection, flow cytometry, Western blot, radio-immunoassay, nephelometry or a histochemical staining is used for the diagnosis.
108. Use of a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, b) occurs on activated human CD4' and CD8 T lymphocytes but not resting or activated B lymphocytes, granulocytes, monocytes, NK cells or dendritic cells, c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and d) comprises an amino-acid sequence which shows at least homology with the sequence comprising 199 amino acid in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes, or comprises the amino acid sequence shown in Fig. 54 0 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a 0 N costimulatory effect on T lymphocytes, Sfor producing antibodies in vitro. S109. A method of producing monoclonal antibodies, wherein B lymphocytes of mice which are immunized with human T lymphocytes activated PMA and the SCa 2 ionophore ionomycin are fused with a myeloma cell line to give an antibody- 00 secreting hybridoma, and the monoclonal antibodies are purified in flow cytometry c for 2 signal molecule-activated against resting T lymphocytes and identified as 0antibodies which specifically recognize a human 8F4 polypeptide, wherein said C 10 human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, b) occurs on activated human CD4 and CD8 T lymphocytes but not resting or activated B lymphocytes, granulocytes, monocytes, NK cells or dendritic cells, c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes.
110. The method according to claim 109, wherein the monoclonal antibody costimulates T lymphocytes.
111. The method according to claim 109, wherein the monoclonal antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide and/or, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates human T lymphocytes.
112. The method according to claim 110, wherein the T lymphocytes are CD4 T lymphocytes. S113. The method according to claim 110, wherein the T lymphocytes are CD8' O N T lymphocytes. V 114. The method according to claim 110, wherein the monoclonal antibody Srecognizes an antigen of about 55 to 60 kDa in a non-reducing SDS-PAGE on activated T lymphocytes. 0 o 115. The method according to claim 109, wherein the monoclonal antibody r recognizes an antigen of about 27 and about 29 kDa in a reducing SDS-PAGE on activated T lymphocytes. (N
116. A medicament comprising an antibody which specifically recognizes a human 8F4 polypeptide, wherein said human 8F4 polypeptide: a) has the biological activity of costimulation of T lymphocytes, b) occurs on activated human CD4 and CD8 T lymphocytes but not resting or activated B lymphocytes, granulocytes, monocytes, NK cells or dendritic cells, c) has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis, and d) comprises the amino acid sequence shown in Fig. 15 (SEQ ID NO:2), or a biologically active fragment thereof showing likewise a costimulatory effect on T lymphocytes; wherein the antibody recognizes 2 signal-activated but not resting T lymphocytes; and wherein the antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide and/or, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates human T lymphocytes.
117. The medicament of claim 116, wherein the antibody is a monoclonal antibody. O 118. A mouse antibody as defined in claim 1 substantially as hereinbefore N described with reference to the Examples.
119. Use of 8F4 polypeptide substantially as hereinbefore described with \D 0 reference to the Examples.
120. A hybridoma that produces a mouse monoclonal antibody that recognises 00 0o human 8F4 polypeptide substantially as hereinbefore described with reference to c the Examples. c- DATED this 4 th day of September 2006 BUNDESREPUBLIK DEUTSCHLAND LETZTVERTRETEN DURCH DEN DIREKTOR DES ROBERT-KOCH-INSTITUS WATERMARK PATENT TRADE MARK ATTORNEYS 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA P17233AU01
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002323894A AU2002323894B2 (en) | 1997-09-23 | 2002-12-19 | Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19741929 | 1997-09-23 | ||
| DE19821060 | 1998-05-11 | ||
| PCT/DE1998/002896 WO1999015553A2 (en) | 1997-09-23 | 1998-09-23 | Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use |
| AU13320/99A AU752433B2 (en) | 1997-09-23 | 1998-09-23 | Costimulating T-cell polypeptide, monoclonal antibodies, their preparation and use |
| AU2002323894A AU2002323894B2 (en) | 1997-09-23 | 2002-12-19 | Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU13320/99A Division AU752433B2 (en) | 1997-09-23 | 1998-09-23 | Costimulating T-cell polypeptide, monoclonal antibodies, their preparation and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002323894A1 AU2002323894A1 (en) | 2003-05-15 |
| AU2002323894B2 true AU2002323894B2 (en) | 2006-10-12 |
Family
ID=39357301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002323894A Ceased AU2002323894B2 (en) | 1997-09-23 | 2002-12-19 | Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2002323894B2 (en) |
-
2002
- 2002-12-19 AU AU2002323894A patent/AU2002323894B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7722872B2 (en) | Treatment of cancer with antibodies to costimulating polypeptide of T cells | |
| US7259247B1 (en) | Anti-human T-cell costimulating polypeptide monoclonal antibodies | |
| JP3722375B2 (en) | CTLA4 receptor, fusion proteins containing it and their use | |
| US20100015153A1 (en) | Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the Same | |
| US6576754B2 (en) | CD100 antigen and uses therefor | |
| EP0660721A1 (en) | Monoclonal antibodies that block ligand binding to the cd22 receptor in mature b cells | |
| JPH09500788A (en) | B7-2: CTLA4 / CD28 counter receptor | |
| JP2000500961A (en) | Novel CTLA4 / CD28 ligand and use thereof | |
| EP1240326B1 (en) | Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify this receptor | |
| AU2002323894B2 (en) | Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use | |
| CA2288307C (en) | Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TC | Change of applicant's name (sec. 104) |
Owner name: BUNDESREPUBLIK DEUTSCHLAND LETZVERTRETEN DURCH DEN Free format text: FORMER NAME: BUNDESREPUBLIK DEUTSCHLAND LETZVERTRETEN DURCH DEN DIREKTOR DES ROBER-KOCH-INSTITUTS |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |